Article Date: 11 Oct 2006 - 0:00 PDT文章日期:2006年10月11日-罢工光动力
| email to a friend | printer friendly | view or write opinions ||电邮给朋友|打印机友好|查看或书写的意见|
Article Also Appears In文章还出现在
- Medical Devices医疗器械
rate this article率这篇文章
InterCure, Ltd., today announced that its RESPeRATE（R） guided breathing technology, clinically-proven in numerous peer-reviewed studies to significantly lower blood pressure, is now in use in more than 50,000 homes worldwide.intercure有限公司今天宣布,其resperate导烟（住宅）科技临床证明,在众多同行审查研究,以降低血压,是目前全世界使用超过五万家. This milestone caps a year of explosive growth for RESPeRATE, doubling its sales over the prior year period, largely via sales through its website, http://www.resperate.com .这一年碑帽resperate爆炸性增长,比前一年增加一倍销售期主要是通过销售通过其网站,http://www.resperate.com.
Seven clinical studies published in peer-reviewed medical journals have demonstrated that RESPeRATE can lower high blood pressure by an average of 14 points systolic and 8 points diastolic.临床研究报告发表在7同行审查医学期刊证明可以降低血压高resperate平均8点14分收缩期及舒张. Because RESPeRATE is not a drug, there are no adverse side effects or drug interactions.因为resperate不是毒品,没有任何不良的副作用或药物的相互作用.
"RESPeRATE is beginning to experience tremendous growth, as a huge group of frustrated hypertension sufferers discover our safe, non-drug treatment option," said Erez Gavish, CEO of InterCure, manufacturer of the RESPeRATE device."resperate开始体验很大增长,一大群愤怒的高血压患者,发现安全非药物治疗方案"埃雷兹Gavish总裁intercure,resperate制造的装置. "Our online and direct marketing programs have yielded a two-fold sales increase over last year. In the coming year, we will significantly accelerate our growth by launching into traditional distribution channels. This channel expansion will allow the 65 million hypertension patients in the U.S. to have broad exposure and easy access to a new approach to blood pressure treatment.""我们的网上直销节目取得了两倍的销售较去年增加.在来年我们将大大加快自己成长的发射进入传统分销渠道.这个渠道扩张将使65000000高血压患者,在美国有广阔的视野和便捷的新途径血压治疗."
InterCure also announced the company is expanding its sales and marketing efforts and accelerating its international expansion.intercure还宣布,该公司正在扩大其销售及市场推广工作,加快国际化进程. The company has hired consumer healthcare marketing executive, Brian Packard, as its Chief Marketing Officer to lead this charge.该公司已聘请消费者保健营销长官布赖恩帕卡德,其首席营销官带领这项指控. Packard comes to InterCure from Philips Medical Systems, where he launched the award-winning HeartStart Home Defibrillator.帕卡德来到intercure由飞利浦医疗系统,在那里他发动获奖heartstart家除颤. Packard will focus on expanding successful online and direct-to-consumer marketing models while positioning the organization for the move to retail distribution.惠普将重点扩大成功网上直接向消费者销售模式定位在零售组织的举措分布.
"The growing body of clinical support, rapid expansion of online and direct-to-consumer sales, and the continued rave reviews from our consumers demonstrate that RESPeRATE is ready for broader channels of distribution," said Packard."越来越多的临床支持,迅速扩展网上直接向消费者销售而从我们消费者继续如潮显示resperate愿广泛流通渠道"帕卡德说. "We will replicate successful sales and marketing approaches from the U.S. and U.K., as we build upon our existing presence in European and Asian markets.""我们将复制成功的营销方式,从美国和英国,正如我们已有的基础,在欧洲及亚洲市场."
Research conducted by the company in conjunction with Ipsos-Vantis among its customer base reveals that 90 percent of RESPeRATE owners surveyed are satisfied with the device and still use it regularly eight to twelve weeks after purchase.该公司进行的研究与驻在国-vantis其中显示,90%的客户基础,拥有resperate调查还满意装置和使用8至12周后定期购买. In the same survey, approximately two-thirds of owners surveyed stated they would definitely recommend RESPeRATE to a friend.在同一调查中,约有三分之二的受访车主表示肯定resperate推荐给朋友.
According to the American Heart Association, more than 65 million Americans have high blood pressure, and even with traditional treatment methods of diet, exercise and medication, 70 percent of that population is either unable to reach their lower blood pressure goals or can't tolerate the side effects of medications.据美国心脏协会,超过6500万美国人的血压高、与传统的治疗方法,甚至饮食、运动及药物治疗,无论是70%,人口达不到他们的血压降低目标或不能容忍方用药效果. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.左未处理,血压高可能会导致心脏病发作、中风、肾脏或心脏衰竭.
About RESPeRATE约resperate
RESPeRATE（R） is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy.resperate（住宅）林业局-清除过量的柜台销售和医疗器械是唯一的临床证实,降低血市场压疗法通过呼吸节奏. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute.该装置利用人体自然倾向遵循外部节奏互动引导使用者用力呼吸速率降低到"治疗区"不到10元息分钟. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.演习resperate呼吸肌肉放松限制小血管周围,让血液更自由地流动,并产生了显着降低血压持久星期.
About InterCure, Ltd.约intercure股份有限公司
InterCure, a medical device company, has become a leader in the growing Personal Therapeutic Device category.intercure,医疗器械公司,已成为越来越多的领导人个人类治疗仪器. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomous nervous system.它大致专利"装置制导烟"的技术平台,使系统减少交感神经的自主神经系统流出. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE（R）.intercure成功推销了世界上第高血压治疗仪,resperate（住宅）. With multiple published clinical trials, regulatory approvals in most key markets （FDA over-the-counter （"OTC"） clearance, CE mark, Chinese SDA and others） and a renowned scientific advisory board, RE SPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension.多发性发表临床试验,大部分主要市场的监管批准（FDA的过度的柜台（"处方"）间隙,CE标志,中国自失等）及知名的科学顾问委员会建议,重新N2迅速成为了部分的标准护理治疗高血压. （ http://www.intercure.com , http://www.resperate.com ）（http://www.intercure.com,http://www.resperate.com）
InterCure, Ltdintercure股份有限公司
http://www.intercure.comhttp://www.intercure.com
（521）
本站将在收悉的第一时间处理该部分内容并给您相应的答复 谢谢合作！